81 related articles for article (PubMed ID: 1296011)
21. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
Wilson TW; Chockalingam A; Quest DW
J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
[TBL] [Abstract][Full Text] [Related]
22. Epidemiological and cost implications of antihypertensive treatment for the prevention of cardiovascular disease.
Grimm RH
J Hum Hypertens; 1989 Dec; 3 Suppl 2():55-60; discussion 60-1. PubMed ID: 2514265
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacotherapy of hypertension. How much can safely be saved?].
Anlauf M
MMW Fortschr Med; 2004 Apr; 146(15):57-8. PubMed ID: 15373022
[No Abstract] [Full Text] [Related]
24. [The cost/benefit of antihypertensive therapy].
Pessina AC
Ann Ital Med Int; 1995 Oct; 10 Suppl():96S-98S. PubMed ID: 8562277
[TBL] [Abstract][Full Text] [Related]
25. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
[TBL] [Abstract][Full Text] [Related]
26. Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Machakos District, Kenya.
Nganda B; Wang'ombe J; Floyd K; Kangangi J
Int J Tuberc Lung Dis; 2003 Sep; 7(9 Suppl 1):S14-20. PubMed ID: 12971650
[TBL] [Abstract][Full Text] [Related]
27. Reply to Kaplan: Coronary Heart Disease Policy Model.
Goldman L; Weinstein MC
Am J Hypertens; 1992 Sep; 5(9):666-9. PubMed ID: 1418857
[No Abstract] [Full Text] [Related]
28. IX-1993 guidelines for management of mild hypertension. WHO/ISH Mild Hypertension Liaison Committee.
Clin Exp Hypertens; 1993 Nov; 15(6):1363-95. PubMed ID: 8268896
[No Abstract] [Full Text] [Related]
29. Differences in medical expenditure according to drug prices.
Ueshima H
Hypertens Res; 2006 May; 29(5):301-2. PubMed ID: 16832148
[No Abstract] [Full Text] [Related]
30. Economic costs and benefits of treating mild hypertension: results from a cross-sectional model.
Millar JA; Hansen PC
N Z Med J; 1988 Oct; 101(855):623-5. PubMed ID: 3140147
[TBL] [Abstract][Full Text] [Related]
31. Assessing the economic value of antihypertensive medicines.
Drummond M; Coyle D
J Hum Hypertens; 1992 Dec; 6(6):495-501. PubMed ID: 1296016
[No Abstract] [Full Text] [Related]
32. Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
Linjer E; Hedner T; Jönsson B; Ekbom T; Lindholm LH; Dahlöf B; de Faire U; Scherstén B;
Blood Press; 2005; 14(2):107-13. PubMed ID: 16036488
[TBL] [Abstract][Full Text] [Related]
33. Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan.
Sakamaki Y; Sasamura H; Ikeda S; Ikegami N; Saruta T
Hypertens Res; 2006 May; 29(5):333-8. PubMed ID: 16832153
[TBL] [Abstract][Full Text] [Related]
34. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden.
Lindblom B; Nordmann JP; Sellem E; Chen E; Gold R; Polland W; Williamson W; Buchholz P; Walt JG; Groleau D; Curry A; Evans SJ
Acta Ophthalmol Scand; 2006 Feb; 84(1):74-83. PubMed ID: 16445443
[TBL] [Abstract][Full Text] [Related]
35. [Investigation and treatment of primary hypertension].
Lindstedt I; Nilsson PM
Lakartidningen; 2008 Jul 23-Aug 5; 105(30-31):2107-12. PubMed ID: 18751450
[No Abstract] [Full Text] [Related]
36. The value of antihypertensive drugs: a perspective on medical innovation.
Cutler DM; Long G; Berndt ER; Royer J; Fournier AA; Sasser A; Cremieux P
Health Aff (Millwood); 2007; 26(1):97-110. PubMed ID: 17211019
[TBL] [Abstract][Full Text] [Related]
37. Economic burden of obesity-related chronic diseases in Mainland China.
Zhao W; Zhai Y; Hu J; Wang J; Yang Z; Kong L; Chen C
Obes Rev; 2008 Mar; 9 Suppl 1():62-7. PubMed ID: 18307701
[TBL] [Abstract][Full Text] [Related]
38. Participation, resource mobilization and financial incentives in community-based health promotion: an economic evaluation perspective from Sweden.
Johansson PM; Eriksson LS; Sadigh S; Rehnberg C; Tillgren PE
Health Promot Int; 2009 Jun; 24(2):177-84. PubMed ID: 19321496
[TBL] [Abstract][Full Text] [Related]
39. Healthy communities: reducing need (and costs!) by promoting health.
Coile RC
Hosp Strategy Rep; 1994 Feb; 6(4):1, 3-5. PubMed ID: 10132281
[No Abstract] [Full Text] [Related]
40. Ambulatory blood pressure monitoring: is it cost-effective?
Krakoff LR; Schechter C; Fahs M; Andre M
J Hypertens Suppl; 1991 Dec; 9(8):S28-30. PubMed ID: 1795198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
